TBPH stock icon

Theravance Biopharma
TBPH

$9.89
1%

Market Cap: 481M

 

About: Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Employees: 99

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 3 analysts
0
News positive %
of 4 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

13% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 16

2% more funds holding

Funds holding: 118 [Q4 2023] → 120 (+2) [Q1 2024]

1.56% more ownership

Funds ownership: 98.02% [Q4 2023] → 99.58% (+1.56%) [Q1 2024]

4% less call options, than puts

Call options by funds: $22K | Put options by funds: $23K

20% less funds holding in top 10

Funds holding in top 10: 5 [Q4 2023] → 4 (-1) [Q1 2024]

22% less capital invested

Capital invested by funds: $549M [Q4 2023] → $430M (-$118M) [Q1 2024]

22% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 46

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$20
102%
upside
Avg. target
$20
106%
upside
High target
$21
112%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Douglas Tsao
102%upside
$20
Buy
Reiterated
29 May 2024
HC Wainwright & Co.
Douglas Tsao
102%upside
$20
Buy
Reiterated
14 May 2024
BTIG
Julian Harrison
112%upside
$21
Buy
Initiated
12 Apr 2024

Financial journalist opinion

Based on 4 articles about TBPH published over the past 30 days